Evolocumab
ApprovedWithdrawn 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Coronary Artery Disease
Conditions
Coronary Artery Disease
Trial Timeline
Aug 30, 2019 → Feb 24, 2023
NCT ID
NCT03851263About Evolocumab
Evolocumab is a approved stage product being developed by HeartFlow for Coronary Artery Disease. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT03851263. Target conditions include Coronary Artery Disease.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03851263 | Approved | Withdrawn |
Competing Products
20 competing products in Coronary Artery Disease